Key result
Targeted ADAMTS7 inhibition represents a possible novel approach to treat coronary artery disease, supported by animal models and human genetic studies linking ADAMTS7 polymorphisms to CAD risk.
Answers are grounded in this paper and cite their sources.
ADAMTS7 inhibition is discussed as a potential novel therapeutic approach for coronary artery disease based on animal and human genetic studies.
Studies in animal models have demonstrated that the protease ADAMTS7 plays a role in neointima formation after arterial mechanical injury, by facilitating vascular smooth muscle cell (VSMC) migration. Furthermore, recent human genetic studies have revealed an association between DNA polymorphisms at the ADAMTS7 gene locus and risk of coronary artery disease (CAD). Functional studies have shown that a CAD-associated polymorphism in the coding region of the ADAMTS7 gene affects ADAMTS7 maturation and VSMC migration. This editorial highlights these findings and discusses targeted ADAMTS7 inhibition as a possible novel approach to treat CAD.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2013) conducted an editorial in Coronary artery disease. Targeted ADAMTS7 inhibition was evaluated. Targeted ADAMTS7 inhibition represents a possible novel approach to treat coronary artery disease, supported by animal models and human genetic studies linking ADAMTS7 polymorphisms to CAD risk.
Synapse has enriched 10 related papers. Consider them for comparative context: